Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12051
Full metadata record
DC FieldValueLanguage
dc.contributor.authorArdipradja, Katieen
dc.contributor.authorYeoh, Shinn Deeen
dc.contributor.authorAlt, Karenen
dc.contributor.authorO'Keefe, Graeme Jen
dc.contributor.authorRigopoulos, Angelaen
dc.contributor.authorHowells, David Williamen
dc.contributor.authorScott, Andrew Men
dc.contributor.authorPeter, Karlheinzen
dc.contributor.authorAckerman, Uween
dc.contributor.authorHagemeyer, Christoph Een
dc.date.accessioned2015-05-16T01:41:47Z
dc.date.available2015-05-16T01:41:47Z
dc.date.issued2013-12-18en
dc.identifier.citationNuclear Medicine and Biology 2013; 41(3): 229-37en
dc.identifier.govdoc24440583en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12051en
dc.description.abstractActivated platelets are key players in thrombosis and inflammation. We previously generated single-chain antibodies (scFv) against ligand-induced binding sites (LIBS) on the highly abundant platelet glycoprotein integrin receptor IIb/IIIa. The aim of this study was the construction and characterisation of a novel (18)F PET radiotracer based on this antibody.ScFv(anti-LIBS) and control antibody mut-scFv were reacted with N-succinimidyl-4-[(18)F]fluorobenzoate (S[(18)F]FB). Radiolabeled scFv was incubated with in vitro formed platelet clots and injected into mice with FeCl(3) induced thrombus in the left carotid artery. Clots were imaged in the PET scanner and amount of radioactivity measured using an ionization chamber and image analysis. Assessment of vessel injury as well as the biodistribution of the radiolabeled scFv was studied.After incubation with increasing concentrations of (18)F-scFv(anti-LIBS) clots had retained significantly higher amounts of radioactivity compared to clots incubated with radiolabeled (18)F-mut-scFv (13.3 ± 3.8 vs. 3.6 ± 1 KBq, p < 0.05, n = 9, decay corrected). In the in vivo experiments we found an high uptake of the tracer in the injured vessel compared with the non-injured vessel, with 12.6 ± 4.7% injected dose per gram (ID/g) uptake in the injured vessel and 3.7 ± 0.9% ID/g in the non-injured vessel 5 minutes after injection (p < 0.05, n = 6).Our results show that the novel antibody radiotracer (18)F-scFv(anti-LIBS) is useful for the sensitive detection of activated platelets and thrombosis.We describe the first (18)F variant of a scFv(anti-LIBS) against activated platelets. This diagnostic agent could provide a powerful tool for the assessment of acute thrombosis and inflammation in patients in the future.en
dc.language.isoenen
dc.subject.otherAntibodiesen
dc.subject.otherPET/CTen
dc.subject.otherPlateletsen
dc.subject.otherThrombosisen
dc.subject.otherAnimalsen
dc.subject.otherBenzoates.chemistryen
dc.subject.otherBlood Coagulationen
dc.subject.otherCarotid Artery Thrombosis.pathology.physiopathology.radionuclide imagingen
dc.subject.otherDisease Models, Animalen
dc.subject.otherFemaleen
dc.subject.otherFluorine Radioisotopes.diagnostic useen
dc.subject.otherImage Processing, Computer-Assisteden
dc.subject.otherMiceen
dc.subject.otherMice, Inbred C57BLen
dc.subject.otherPlatelet Activationen
dc.subject.otherPositron-Emission Tomographyen
dc.subject.otherSingle-Chain Antibodies.chemistry.diagnostic use.pharmacokineticsen
dc.titleDetection of activated platelets in a mouse model of carotid artery thrombosis with 18 F-labeled single-chain antibodies.en
dc.typeJournal Articleen
dc.identifier.journaltitleNuclear medicine and biologyen
dc.identifier.affiliationAtherothrombosis and Vascular Biology Laboratory, Baker IDI, Melbourne, Australiaen
dc.identifier.affiliationVascular Biotechnology Laboratory, Baker IDI, Melbourne, Australiaen
dc.identifier.affiliationCentral Clinical School, Monash University, Melbourne, Australiaen
dc.identifier.affiliationDepartment of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australiaen
dc.identifier.affiliationDepartments of Nuclear Medicine and Centre for PET, Austin Hospital, Melbourne, Australiaen
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health, Austin Hospital, Melbourne, Australiaen
dc.identifier.affiliationLudwig Institute for Cancer Research, Austin Hospital, Melbourne, Australiaen
dc.identifier.doi10.1016/j.nucmedbio.2013.12.006en
dc.description.pages229-37en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/24440583en
dc.type.austinJournal Articleen
local.name.researcherScott, Andrew M
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.